Price
Financials
Standalone, Rs crore| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 17.02 | 19.13 | 19.31 | 20.71 | 24.06 | 26.60 | 33.29 | 39.84 |
| Expenses | 13.71 | 14.82 | 15.02 | 16.42 | 19.16 | 21.42 | 27.03 | 33.37 |
| Operating Profit | 3.31 | 4.31 | 4.29 | 4.29 | 4.90 | 5.18 | 6.26 | 6.47 |
| OPM % | 19.45% | 22.53% | 22.22% | 20.71% | 20.37% | 19.47% | 18.80% | 16.24% |
| Other Income | 0.00 | -0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest | 0.01 | 0.01 | 0.05 | 0.00 | 0.07 | 0.06 | 0.06 | 0.05 |
| Depreciation | 0.08 | 0.08 | 0.12 | 0.13 | 0.10 | 0.17 | 0.19 | 0.22 |
| Profit before tax | 3.22 | 3.77 | 4.12 | 4.16 | 4.73 | 4.95 | 6.01 | 6.21 |
| Tax % | 25.47% | 25.46% | 24.76% | 25.00% | 25.16% | 25.05% | 25.29% | 27.05% |
| Net Profit | 2.40 | 2.81 | 3.10 | 3.12 | 3.54 | 3.70 | 4.50 | 4.53 |
| EPS in Rs | 49.59 | 3.63 | 2.68 | 2.70 | 3.06 | 3.20 | 3.89 | 2.73 |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.09 | 29.95 | 30.07 | 22.48 | 30.06 | 36.15 | 39.93 | 50.64 | 73.02 |
| Expenses | 27.94 | 30.65 | 29.83 | 22.29 | 27.01 | 28.00 | 31.14 | 40.57 | 60.29 |
| Operating Profit | 0.15 | -0.70 | 0.24 | 0.19 | 3.05 | 8.15 | 8.79 | 10.07 | 12.73 |
| OPM % | 0.53% | -2.34% | 0.80% | 0.85% | 10.15% | 22.54% | 22.01% | 19.89% | 17.43% |
| Other Income | 0.00 | 0.83 | 0.01 | 0.01 | 0.00 | -0.97 | 0.00 | 0.01 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.02 | 0.08 | 0.03 | 0.26 | 0.13 | 0.12 |
| Depreciation | 0.10 | 0.07 | 0.13 | 0.12 | 0.17 | 0.16 | 0.25 | 0.27 | 0.41 |
| Profit before tax | 0.05 | 0.06 | 0.11 | 0.06 | 2.80 | 6.99 | 8.28 | 9.68 | 12.22 |
| Tax % | 20.00% | 16.67% | 27.27% | 33.33% | 26.79% | 25.46% | 25.12% | 25.21% | 26.19% |
| Net Profit | 0.05 | 0.05 | 0.08 | 0.04 | 2.06 | 5.21 | 6.20 | 7.24 | 9.03 |
| EPS in Rs | 1.10 | 1.10 | 1.76 | 0.83 | 42.56 | 6.73 | 5.36 | 6.26 | 5.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 10% | 27% | 26% | 44% | ||
| Compounded Profit Growth | 68% | 196% | 15% | 25% | ||
| Stock Price CAGR | % | % | -4% | -15% | ||
| Return on Equity | % | 21% | 18% | 15% |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.45 | 0.45 | 0.45 | 0.48 | 0.48 | 7.74 | 11.56 | 11.56 | 16.61 |
| Reserves | 7.31 | 7.32 | 6.53 | 6.63 | 8.32 | 6.81 | 24.26 | 31.16 | 60.02 |
| Borrowings | 2.07 | 0.11 | 0.24 | 0.00 | 0.13 | 1.78 | 0.58 | 1.04 | 0.80 |
| Other Liabilities | 1.73 | 3.76 | 3.41 | 3.09 | 3.91 | 5.12 | 1.51 | 4.58 | 6.80 |
| Total Liabilities | 11.56 | 11.64 | 10.63 | 10.20 | 12.84 | 21.45 | 37.91 | 48.34 | 84.23 |
| Fixed Assets | 2.61 | 2.71 | 1.77 | 1.57 | 1.45 | 2.52 | 4.26 | 5.96 | 7.14 |
| CWIP | 0.14 | 0.11 | 0.00 | 0.00 | 0.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.68 | 0.68 | 0.68 | 0.00 | 0.00 | 0.68 | 0.68 |
| Other Assets | 8.81 | 8.82 | 8.18 | 7.95 | 10.16 | 18.93 | 33.65 | 41.70 | 76.41 |
| Total Assets | 11.56 | 11.64 | 10.63 | 10.20 | 12.84 | 21.45 | 37.91 | 48.34 | 84.23 |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.00 | -0.27 | -0.28 | 0.52 | 0.00 | -1.96 | 5.42 | -12.48 | |
| Cash from Investing Activity | 0.00 | 0.29 | 0.03 | -0.85 | 0.11 | -4.43 | -7.13 | -14.55 | |
| Cash from Financing Activity | 0.00 | 0.00 | 0.48 | 0.06 | 0.21 | 11.01 | 0.09 | 24.69 | |
| Net Cash Flow | 0.00 | 0.02 | 0.23 | -0.27 | 0.33 | 4.61 | -1.62 | -2.34 | |
| Free Cash Flow | 0.00 | -0.32 | -0.29 | -0.08 | 0.00 | -2.81 | 2.77 | -14.07 | |
| CFO/OP | 0% | -112% | -147% | 17% | 0% | -5% | 78% | -73% |
| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.99 | 14.14 | 7.40 | 12.34 | 19.55 | 82.69 | 80.90 | 68.26 | 59.03 |
| Inventory Days | 61.39 | 49.67 | 55.59 | 69.41 | 80.06 | 110.68 | 125.33 | 127.15 | 160.53 |
| Days Payable | 2.49 | 2.16 | 3.35 | 5.35 | 4.52 | 6.54 | 8.96 | 12.32 | 8.21 |
| Cash Conversion Cycle | 71.89 | 61.65 | 59.64 | 76.40 | 95.09 | 186.84 | 197.26 | 183.09 | 211.35 |
| Working Capital Days | 91.35 | 59.59 | 54.14 | 74.85 | 71.64 | 121.57 | 212.07 | 181.85 | 234.79 |
| ROCE % | 0.68% | 1.12% | 35.91% | 63.26% | 32.39% | 24.48% | 20.36% |
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Nov 2025 | Mar 2026 | May 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 56.89% | 56.89% | 54.97% | 52.32% | 52.32% | 47.19% | 44.99% | 44.38% |
| Public | 43.11% | 43.12% | 45.03% | 47.68% | 47.68% | 52.82% | 55.00% | 55.61% |
| No. of Shareholders | 836 | 868 | 1,119 | 1,153 | 1,094 | 1,093 | 1,060 | 1,089 |
Fundamentals
Market Cap₹ 58.9 Cr.
Current Price₹ 35.0
Stock P/E6.51
Book Value₹ 46.1
ROCE20.4 %
ROE15.1 %
Dividend Yield1.01 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)44%
Compounded Profit Growth (TTM)25%
Standalone figures.
Valuation
Market capRs 42 Cr
Enterprise valueRs 40 Cr
P/E (TTM)5.79x
Price to book0.98x
Price to sales0.83x
EV / EBITDA3.92x
EV / EBIT4.03x
EV / sales0.78x
Price to cash flow7.73x
Earnings yield17.28%
P/E, 3-year average7.47x
P/B, 3-year average1.28x
P/E, 5-year average7.47x
P/B, 5-year average1.28x
Profitability
Operating margin (excl. other income)19.89%
Operating margin (incl. other income)19.91%
EBITDA margin19.91%
Pre-tax margin19.12%
Net profit margin14.30%
ROE18.44%
ROCE24.48%
ROA16.79%
ROE, 3-year average29.23%
ROCE, 3-year average37.48%
ROA, 3-year average22.69%
ROE, 5-year average22.83%
ROCE, 5-year average29.90%
ROA, 5-year average17.27%
ROIC (approx.)18.19%
Tax rate25.21%
Other income / net worth0.02%
Growth
Sales growth (latest year)26.82%
Profit growth (latest year)16.77%
Sales CAGR, 3 years18.99%
Sales CAGR, 5 years10.99%
Profit CAGR, 3 years52.04%
Profit CAGR, 5 years146.22%
Per share
EPS (TTM)Rs 6.26
EPS (latest year)Rs 6.26
EPS, 3-year averageRs 6.12
EPS, 5-year averageRs 12.35
Book value per shareRs 36.96
Sales per shareRs 43.81
Cash flow per shareRs 4.69
Free cash flow per shareRs -12.17
Efficiency
Asset turnover1.05x
Fixed asset turnover8.50x
Inventory turnover2.91x
Inventory days126 days
Debtor days68 days
Debtors turnover5.35x
Creditor days8 days
Cash conversion cycle211 days
Working capital days235 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 3 Cr
Net debtRs -2 Cr
Debt to equity0.02x
Net debt / EBITDA-0.24x
Interest coverage75.46x
Owners' fund to total sources88.37%
Debt to assets2.15%
Cash flow
Cash from Operating Activity (latest year)Rs 5 Cr
Cash from Investing Activity (latest year)Rs -7 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs -14 Cr
FCFE (approx.: FCF + change in debt)Rs -14 Cr
Cash from ops / profit, 5 years-0.29x
Sales to cash flow9.34x
Statement figures
Net sales (TTM)Rs 51 Cr
Net sales (latest year)Rs 51 Cr
Operating profit excl. other income (latest year)Rs 10 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 10 Cr
PBDT (TTM)Rs 10 Cr
Profit before tax (TTM)Rs 10 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 7 Cr
Net profit (latest year)Rs 7 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 37 Cr
Total expenditure (latest year)Rs 41 Cr
Total income (latest year)Rs 51 Cr
Share capitalRs 12 Cr
ReservesRs 31 Cr
Shareholders' fundsRs 43 Cr
Total assetsRs 48 Cr
Net blockRs 6 Cr
InvestmentsRs 1 Cr
ReceivablesRs 9 Cr
InventoryRs 13 Cr
Other liabilitiesRs 5 Cr
Shares outstanding (crore)1.16
Ownership
Promoter holding44.38% (-7.94 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 5.8 is at the 13th percentile of its own 3.2-year range
(median 9.2, low 4.3, high 36.8).
P/B 0.98 is at the 10th percentile (median 3.28).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 543963 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -4.6% | -2.8% | -1.8 pts |
| 1 month | +14.4% | -6.8% | +21.1 pts |
| 3 months | +26.7% | -7.6% | +34.3 pts |
| 3 years | -13.3% | +14.2% | -27.5 pts |
Red flags
F-score 3 of 8| explain | Share dilution Share count up 0% in a year, 2220% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹40 Cr +92.4% vs Mar 2024.
Net profit ₹5 Cr +45.2%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Shelter Pharma Ltd?
Shelter Pharma Ltd (543963) has a market capitalisation of Rs 58.9 Cr. at the 2026-10-01 close.
What is the P/E ratio of Shelter Pharma Ltd?
Shelter Pharma Ltd trades at a P/E of 6.51 on trailing twelve-month profit, at the 2026-10-01 close.
What were Shelter Pharma Ltd's latest quarterly results?
In the Mar 2026 quarter, Shelter Pharma Ltd sales was Rs 40 Cr (+92.4% vs Mar 2024) and net profit was Rs 5 Cr.